Analysts Set Agios Pharmaceuticals, Inc. (NASDAQ:AGIO) Target Price at $63.71

Shares of Agios Pharmaceuticals, Inc. (NASDAQ:AGIO) have been given an average rating of “Buy” by the fourteen research firms that are presently covering the company, Marketbeat.com reports. Five investment analysts have rated the stock with a hold rating and nine have given a buy rating to the company. The average 1 year price objective among brokers that have updated their coverage on the stock in the last year is $68.71.

A number of equities analysts recently weighed in on the company. Canaccord Genuity set a $90.00 price objective on Agios Pharmaceuticals and gave the company a “buy” rating in a report on Wednesday. Leerink Swann raised Agios Pharmaceuticals from a “market perform” rating to an “outperform” rating and raised their price objective for the company from $50.00 to $80.00 in a report on Wednesday. Janney Montgomery Scott reissued a “hold” rating on shares of Agios Pharmaceuticals in a report on Tuesday, August 1st. BidaskClub raised Agios Pharmaceuticals from a “hold” rating to a “buy” rating in a report on Thursday, July 13th. Finally, ValuEngine raised Agios Pharmaceuticals from a “sell” rating to a “hold” rating in a report on Thursday, June 22nd.

In other news, Director Lewis Clayton Jr. Cantley sold 2,000 shares of Agios Pharmaceuticals stock in a transaction that occurred on Wednesday, June 14th. The stock was sold at an average price of $50.87, for a total value of $101,740.00. Following the sale, the director now directly owns 90,197 shares in the company, valued at approximately $4,588,321.39. The sale was disclosed in a filing with the SEC, which is available through this link. Also, CEO David P. Schenkein sold 27,000 shares of Agios Pharmaceuticals stock in a transaction that occurred on Wednesday, August 2nd. The stock was sold at an average price of $59.95, for a total value of $1,618,650.00. Following the completion of the sale, the chief executive officer now owns 3,000 shares in the company, valued at $179,850. The disclosure for this sale can be found here. Over the last quarter, insiders sold 79,120 shares of company stock worth $4,557,207. Corporate insiders own 10.55% of the company’s stock.

Several large investors have recently added to or reduced their stakes in AGIO. C WorldWide Group Holding A S purchased a new stake in Agios Pharmaceuticals during the first quarter valued at $105,000. Bank of Montreal Can raised its stake in Agios Pharmaceuticals by 11.7% in the first quarter. Bank of Montreal Can now owns 2,068 shares of the biopharmaceutical company’s stock valued at $121,000 after buying an additional 216 shares in the last quarter. Blue Sky Asset Management LLC purchased a new stake in Agios Pharmaceuticals during the first quarter valued at $129,000. Russell Investments Group Ltd. raised its stake in Agios Pharmaceuticals by 163.9% in the first quarter. Russell Investments Group Ltd. now owns 2,549 shares of the biopharmaceutical company’s stock valued at $149,000 after buying an additional 1,583 shares in the last quarter. Finally, Advantage Investment Management LLC raised its stake in Agios Pharmaceuticals by 109.7% in the first quarter. Advantage Investment Management LLC now owns 3,250 shares of the biopharmaceutical company’s stock valued at $190,000 after buying an additional 1,700 shares in the last quarter. Institutional investors own 84.24% of the company’s stock.

Agios Pharmaceuticals (NASDAQ AGIO) traded down 2.51% on Monday, hitting $61.46. The stock had a trading volume of 477,021 shares. The stock’s market capitalization is $2.96 billion. The company has a 50-day moving average price of $55.14 and a 200-day moving average price of $50.99. Agios Pharmaceuticals has a 1-year low of $35.84 and a 1-year high of $67.74.

Agios Pharmaceuticals (NASDAQ:AGIO) last announced its quarterly earnings data on Thursday, May 4th. The biopharmaceutical company reported ($1.56) earnings per share for the quarter, beating the Zacks’ consensus estimate of ($1.80) by $0.24. The company had revenue of $10.51 million for the quarter, compared to analysts’ expectations of $9.65 million. Agios Pharmaceuticals had a negative return on equity of 71.20% and a negative net margin of 491.54%. Agios Pharmaceuticals’s revenue for the quarter was down 66.4% compared to the same quarter last year. During the same period last year, the firm posted ($0.64) EPS. Equities analysts predict that Agios Pharmaceuticals will post ($6.43) earnings per share for the current year.

Agios Pharmaceuticals Company Profile

Agios Pharmaceuticals, Inc is a clinical-stage biopharmaceutical company. The Company’s therapeutic areas of focus are cancer and rare genetic metabolic disorders, which are a group of over 600 rare genetic diseases caused by mutations, or defects, of single metabolic genes. The Company’s cancer product candidates are enasidenib and ivosidenib (AG-120), which target mutated isocitrate dehydrogenase 2 (IDH2) and isocitrate dehydrogenase 1 (IDH1), respectively, and AG-881, which targets both mutated IDH1 and mutated IDH2.